Navigation Links
CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
Date:3/9/2009

ase III clinical trial and recently CEL-SCI took delivery of its new state of the art manufacturing facility.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

CEL-SCI has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. Most recently CEL-SCI announced that its newly discovered rheumatoid arthritis vaccine showed excellent results in animal tests. www.cel-sci.com.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
2. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
3. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
4. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
5. CEL-SCI Corporation Releases Letter to Shareholders
6. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
7. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
8. Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information
9. Victory Pharma Announces $45 Million Equity Financing
10. Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing
11. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 29, 2015 , ... People who have ... (including emphysema), or asthma, are at higher risk from wildfire smoke especially in ... failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air ...
(Date:8/28/2015)... ... 28, 2015 , ... Joining a growing number of hospitals ... management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA provides ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
(Date:8/28/2015)... ... ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse treatment ... benefit concert in Mendon, IL. Held in the Show Barn at the Adams County ... programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. Now ...
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and ... James Strawbridge, gives a new approach on solutions in his new book ":Unraveling ... employer and employees getting together for meaningful group meetings. "This would educate the ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... shows droplets rubbed into skin prevented infections , , THURSDAY, ... rubbed into the skin appear to protect against ear ... , If this approach proves effective in humans, it ... infections, the researchers noted. , Three groups of chinchillas ...
... Rockville, Md., May 21, 2009 In an ... of medicines in Peru and the surrounding region, ... Nacional de Control de Calidad (CNCC)has attained internationally ... laboratories. This achievement is being celebrated today in ...
... N.J., May 21 When little Max Kornhauser ... that Max,s head was becoming very flat on one side. ... develop when babies rest for prolonged periods in one position ... be acquired as a result of crowding intra utero or ...
... /PRNewswire/ - With the Alberta Government,s May 20th announcement ... Alberta has completed the funding puzzle and is pleased ... will play a leading role in genomic research.Helping Energy ... hydrocarbon deposits are naturally occurring microbes that have been ...
... found that bipolar disorder is more costly than other ... artery disease. These findings are based on a review ... costs of seeing any specialist and all tests ordered) ... review are being presented today at the Annual Meeting ...
... procedures is lip enhancement. ,The lips are the first thing that most ... surgeon in Albuquerque and Santa Fe New Mexico. , ... (Vocus) May ... enhancement. ,The lips are the first thing that most people notice about ...
Cached Medicine News:Health News:Pediatric Ear Infection Vaccine Shows Promise 2Health News:Medication quality in Peru and region strengthened with official laboratory's accreditation 2Health News:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of New Jersey Children 2Health News:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of New Jersey Children 3Health News:Genomics for a Greener World 2Health News:Genomics for a Greener World 3Health News:Dr. Daniel Ronel Offers New Permanent Lip Enhancement in New Mexico 2
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Bevacizumab ... Developed by Roche under the trade name of Avastin, ... world. In Feb.26, 2010, it was approved by CFDA ... in China all come from ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Bevacizumab Market 2015-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... N.J., Dec. 29, 2011 Janssen Research & Development, LLC ... Drug Application (sNDA) to the U.S. Food and Drug Administration ... (rivaroxaban), an oral anticoagulant, to reduce the risk of (thrombotic) ... The filing is supported by data from the pivotal ...
...  Watson Pharmaceuticals, Inc. (NYSE: WPI ), a ... Watson,s President and Chief Executive Officer, will provide an ... 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January ... am Eastern Standard Time) at the Westin St. Francis ...
Cached Medicine Technology:Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference 2
The control unit manage patient temperatures during long complex surgical procedures to help achieve optimal clinical outcomes....
... The T5002 has it's temperature ... and confirmed by pressing a button. ... is on and a flashing amber ... the required temperature. A red LED ...
The Cocoon Convective Warming Machine is lightweight, compact and easy to use....
The Equator Convective Warmer incorporates LEVEL 1's unique, patented, temperature control technology to ensure delivery of the desired therapy to the patient....
Medicine Products: